Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
Circulating tumor DNA (ctDNA) has contributed immensely to the management of hematologic malignancy and is now considered a valuable detection tool for solid tumors. ctDNA can reflect the real-time tumor burden and be utilized for analyzing specific cancer mutations via liquid biopsy which is a non-...
Main Authors: | Xiaoxu Fang, Shaokun Yu, Yingying Jiang, Yan Xiang, Kaihua Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1027664/full |
Similar Items
-
Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives
by: Eleni Zografos, et al.
Published: (2022-10-01) -
Role of Circulating Tumor DNA in Hematological Malignancy
by: Miho Ogawa, et al.
Published: (2021-04-01) -
Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives
by: Giulia Grizzi, et al.
Published: (2023-05-01) -
Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
by: Lemei Zhu, et al.
Published: (2023-08-01) -
Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
by: Lionel Larribère, et al.
Published: (2021-11-01)